As of Feb 23
| +0.16 / +4.31%|
The 3 analysts offering 12-month price forecasts for ZIOPHARM Oncology Inc have a median target of 9.50, with a high estimate of 23.00 and a low estimate of 5.00. The median estimate represents a +145.48% increase from the last price of 3.87.
The current consensus among 5 polled investment analysts is to Hold stock in ZIOPHARM Oncology Inc. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.